This list can be updated further with the development of nucleoside-based nanomedicines for the treatment of hereditary transthyretin-mediated amyloidosis (Onpattro®) and prophylaxis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (Comirnaty® developed by Pfizer/BioNTech Pfizer, New York, NY, USA-BioNTech, Mainz, Germany and spikevaxTM developed by Moderna Cambridge, MA, USA, both are injectable suspensions for intramuscular use). The gene discussed is TTR; the disease is amyloidosis.